Market news

Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.

Mereo BioPharma will be eligible for $40m in upfront and research and development payments, and up to $435m in milestones.

The rare-disease biotech cut its quarterly net loss while a new Sentynl agreement could provide $40 million in upfront and R&D payments and funding for alvelestat’s planned Phase 3 study. Key Investor TakeawaysMereo BioPharma (NASDAQ:MREO) extended its cash runway guidance into late 2027, ending June with $30.

Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026 Cash and cash equivalents of $30.1 million at June 30, 2026, now expected to fund operations into late-2027 LONDON, Aug. 11, 2026 (

Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global (NASDAQ:OGI)

LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (Nasdaq: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl...